Provectus Biopharmaceuticals IncProvectus Biopharmaceuticals Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This assessment of Provectus Biopharmaceuticals Inc incorporates information from across the internet and also from available filings by Provectus Biopharmaceuticals Inc. Jump to the bottom of the page for potential risks for Provectus Biopharmaceuticals Inc based on industry, location and size. The ESG rating includes 17 United Nations SDGs including: 'Clean Water & Sanitation', 'Sustainable Cities & Communities' and 'Partnerships for the Goals'.

Provectus Biopharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 4.0, social score of 8.0 and governance score of 8.0.

SDG Transparency Score for Provectus Biopharmaceuticals Inc 
Low
0 - 3

6.7

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Provectus Biopharmaceuticals Inc 
4.0

Environmental

8.0

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
314Trulieve Cannabis Corp
6.8
High
314Vicore Pharma Holding AB
6.8
High
337Provectus Biopharmaceuticals Inc
6.7
High
337Calyxt Inc
6.7
High
337CanSino Biologics Inc
6.7
High
.........
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Provectus Biopharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc offer flexible work?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose water use targets?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Provectus Biopharmaceuticals Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Provectus Biopharmaceuticals Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Provectus Biopharmaceuticals Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose its waste policy?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose energy use targets?

LockedSign up for free to unlock

Does Provectus Biopharmaceuticals Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Provectus Biopharmaceuticals Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Provectus Biopharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.

Sorry!

Failed to process!